GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kimia Biosciences Ltd (BOM:530313) » Definitions » Cash-to-Debt

Kimia Biosciences (BOM:530313) Cash-to-Debt : 0.00 (As of . 20)


View and export this data going back to 2017. Start your Free Trial

What is Kimia Biosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Kimia Biosciences's cash to debt ratio for the quarter that ended in . 20 was 0.00.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Kimia Biosciences couldn't pay off its debt using the cash in hand for the quarter that ended in . 20.

The historical rank and industry rank for Kimia Biosciences's Cash-to-Debt or its related term are showing as below:

BOM:530313's Cash-to-Debt is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.93
* Ranked among companies with meaningful Cash-to-Debt only.

Kimia Biosciences Cash-to-Debt Historical Data

The historical data trend for Kimia Biosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Kimia Biosciences Cash-to-Debt Chart

Kimia Biosciences Annual Data
Trend
Cash-to-Debt

Kimia Biosciences Semi-Annual Data
Cash-to-Debt

Competitive Comparison of Kimia Biosciences's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Kimia Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kimia Biosciences's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kimia Biosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Kimia Biosciences's Cash-to-Debt falls into.



Kimia Biosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Kimia Biosciences's Cash to Debt Ratio for the fiscal year that ended in . 20 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

Kimia Biosciences's Cash to Debt Ratio for the quarter that ended in . 20 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kimia Biosciences  (BOM:530313) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Kimia Biosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Kimia Biosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Kimia Biosciences (BOM:530313) Business Description

Traded in Other Exchanges
N/A
Address
Netaji Subhash Place, 974, 9th Floor, Aggarwal Millenium Tower-II, Pitampura, New Delhi, IND, 110 034
Kimia Biosciences Ltd is a company engaged in the manufacturing of bulk drugs. Some of the company's products include Azelnidipine, Deflazacort, Oxaceprol, Seratodast, and Tretinoin among others. Its only operating segment being Pharmaceuticals.

Kimia Biosciences (BOM:530313) Headlines

No Headlines